These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 2994402)

  • 21. Epidemiologic aspects of Epstein-Barr virus (EBV)-associated diseases.
    Henle W; Henle G
    Ann N Y Acad Sci; 1980; 354():326-31. PubMed ID: 6261650
    [No Abstract]   [Full Text] [Related]  

  • 22. A prospective study of antibodies to Epstein-Barr virus DNase and viral capsid antigen for prognostication of patients with nasopharyngeal carcinoma.
    Hsu MM; Chen JY; Chen CJ
    Taiwan Yi Xue Hui Za Zhi; 1988 Oct; 87(10):984-8. PubMed ID: 2853721
    [No Abstract]   [Full Text] [Related]  

  • 23. [IgG and IgA antibodies to the Epstein-Barr virus and nasopharyngeal carcinoma].
    Vera Sempere FJ
    Med Clin (Barc); 1992 May; 98(19):758-9. PubMed ID: 1318986
    [No Abstract]   [Full Text] [Related]  

  • 24. [Distribution of EBV-VCA and EA antibody in the general population in a high incidence area of nasopharyngeal carcinoma].
    Liu YX
    Zhonghua Zhong Liu Za Zhi; 1983 Sep; 5(5):337-9. PubMed ID: 6317314
    [No Abstract]   [Full Text] [Related]  

  • 25. Neutralizing EBV-specific IgA in throat washings of nasopharyngeal carcinoma (NPC) patients.
    Desgranges C; De-Thé G; Ho JH; Ellouz R
    Int J Cancer; 1977 May; 19(5):627-33. PubMed ID: 193801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunoglobulin A against viral capsid antigen of Epstein-Barr virus and indirect mirror examination of the nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma.
    Zong YS; Sham JS; Ng MH; Ou XT; Guo YQ; Zheng SA; Liang JS; Qiu H
    Cancer; 1992 Jan; 69(1):3-7. PubMed ID: 1309307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Detection of IgA serum antibodies to EB virus VCA in patients having survived nasopharyngeal cancer for over 15 years (author's transl)].
    Tang ZH
    Zhonghua Yi Xue Za Zhi; 1982 Mar; 62(3):167-9. PubMed ID: 6286059
    [No Abstract]   [Full Text] [Related]  

  • 28. The efficacy of fiberoptic endoscopic examination and biopsy in the detection of early nasopharyngeal carcinoma.
    Wei WI; Sham JS; Zong YS; Choy D; Ng MH
    Cancer; 1991 Jun; 67(12):3127-30. PubMed ID: 1646070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Presence of Epstein-Barr virus specific IgA in saliva of nasopharyngeal carcinoma patients: their activity, origin and possible clinical value.
    Desgranges C; de-The G
    IARC Sci Publ (1971); 1978; (20):459-69. PubMed ID: 215528
    [No Abstract]   [Full Text] [Related]  

  • 30. [Undifferentiated carcinoma of the nasopharynx associated with the Epstein-Barr virus. Diagnostic value of EBV serology].
    Souillet G; Maisonneuve J; Lenoir G; Gilly J; Brunat-Mentigny M; Duc H; Hermier M
    Pediatrie; 1980 Sep; 35(6):541-4. PubMed ID: 6255403
    [No Abstract]   [Full Text] [Related]  

  • 31. Antibody to Epstein-Barr virus-specific DNase as a marker for field survey of patients with nasopharyngeal carcinoma in Taiwan.
    Chen JY; Chen CJ; Liu MY; Cho SM; Hsu MM; Lynn TC; Shieh T; Tu SM; Beasley RP; Hwang LY
    J Med Virol; 1989 Apr; 27(4):269-73. PubMed ID: 2542436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of antibodies to Epstein-Barr virus in Italian patients with nasopharyngeal carcinoma.
    Cevenini R; Donati M; Caliceti U; Moroni A; Tamba I; Rumpianesi F
    J Infect; 1986 Mar; 12(2):127-31. PubMed ID: 3009628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of IgA antibody to EBV membrane antigen using Staphylococcus aureus preabsorbed sera is closely associated with nasopharyngeal carcinoma.
    Pi GH; Zeng Y; Wolf H
    J Virol Methods; 1987 Jan; 15(1):33-9. PubMed ID: 3027115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnosis of nasopharyngeal carcinoma by means of recombinant Epstein-Barr virus proteins.
    Littler E; Baylis SA; Zeng Y; Conway MJ; Mackett M; Arrand JR
    Lancet; 1991 Mar; 337(8743):685-9. PubMed ID: 1672175
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Detection of early NPC from VCA/IgA antibody positive individuals with anticomplement immunoenzymatic method].
    Zeng Y; Shen SJ; Deng H; Ma JL; Zhang Q; Zhu JS; Cheng JR
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1982 Aug; 4(4):254-5. PubMed ID: 6295651
    [No Abstract]   [Full Text] [Related]  

  • 36. [125I] Clq-binding activity and its relationship with anti-Epstein--Barr virus antibodies in sera from nasopharyngeal carcinoma patients.
    Lamelin JP; Vincent C; Souissi T; Revillard JP
    Eur J Cancer (1965); 1979 Feb; 15(2):163-71. PubMed ID: 220051
    [No Abstract]   [Full Text] [Related]  

  • 37. Nasopharyngeal carcinoma: significance of changes in Epstein-Barr virus-related antibody patterns following therapy.
    Henle W; Ho JH; Henle G; Chau JC; Kwan HC
    Int J Cancer; 1977 Nov; 20(5):663-72. PubMed ID: 200569
    [No Abstract]   [Full Text] [Related]  

  • 38. Nasopharyngeal carcinoma in American Children: Epstein-Barr virus-specific antibody titers and prognosis.
    Naegele RF; Champion J; Murphy S; Henle G; Henle W
    Int J Cancer; 1982 Feb; 29(2):209-12. PubMed ID: 6174465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Further studies on antibodies to early antigens induced by Epstein-Barr virus in nasopharyngeal carcinoma patients.
    Ida S; Hinuma Y; Chu CT; Chiou JF; Lai JG
    Gan; 1973 Dec; 64(6):545-53. PubMed ID: 4360581
    [No Abstract]   [Full Text] [Related]  

  • 40. Screening for nasopharyngeal carcinoma.
    Lancet; 1984 Jul; 2(8393):20-2. PubMed ID: 6145937
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.